Immuneering (NASDAQ:IMRX) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Immuneering (NASDAQ:IMRX) posted its quarterly earnings results on Tuesday. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.05, Yahoo Finance reports.

Immuneering Price Performance

Shares of NASDAQ IMRX opened at $1.14 on Thursday. The firm’s 50-day moving average price is $1.31 and its 200-day moving average price is $2.85. Immuneering has a 52-week low of $1.05 and a 52-week high of $10.47. The company has a market cap of $33.80 million, a PE ratio of -0.61 and a beta of -0.61.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Needham & Company LLC restated a “buy” rating and set a $15.00 price objective on shares of Immuneering in a research note on Wednesday. Chardan Capital reduced their price target on shares of Immuneering from $16.00 to $12.00 and set a “buy” rating for the company in a research report on Wednesday. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $12.60.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.